08.07.24
Lonza, a global partner to the pharmaceutical, biotech, and nutraceutical markets, added clinical bottling and labeling capabilities at its Small Molecules site in Bend, OR. Building upon the recent investment in the early-phase clinical manufacturing facility, the offering now includes new bottling equipment for filling tablets and powder-filled capsules. The additional equipment aims to further support customers in the early stages of development.
The new equipment can detect defects in tablets and capsules as well as clean, fill, cap and seal, and label bottles intended for use in early-phase clinical trials. This aims to enable Lonza to speed up product delivery to clinical trial centers.
Matthew Ferguson, Senior Director, Product Development, Small Molecules, Lonza, said, “Lonza’s Drug Product Formulation and Development Services, offered from our site in Bend (US), supports clinical and commercial development and manufacturing. The new bottling equipment for filling tablets and powder-filled capsules further enhances our ability to support customers looking to accelerate their candidate pathway through phase I and II clinical trials and beyond.”
The new equipment can detect defects in tablets and capsules as well as clean, fill, cap and seal, and label bottles intended for use in early-phase clinical trials. This aims to enable Lonza to speed up product delivery to clinical trial centers.
Matthew Ferguson, Senior Director, Product Development, Small Molecules, Lonza, said, “Lonza’s Drug Product Formulation and Development Services, offered from our site in Bend (US), supports clinical and commercial development and manufacturing. The new bottling equipment for filling tablets and powder-filled capsules further enhances our ability to support customers looking to accelerate their candidate pathway through phase I and II clinical trials and beyond.”
